The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
PreviousPrevious
Volume 356:4-6 January 4, 2007 Number 1
NextNext

Medicare and Erythropoietin
Robert Steinbrook, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Since Medicare coverage of care for end-stage renal disease (ESRD) was implemented in 1973, dialysis treatments paid for by the federal government have extended the lives of hundreds of thousands of people. For nearly two decades, one of the most important services has been the administration of recombinant human erythropoietin, or epoetin, the mainstay of the treatment of anemia associated with chronic renal failure. In 2005, the ESRD program covered about 390,000 beneficiaries and spent $7.9 billion for dialysis services, including $2.9 billion for medications that are reimbursed separately. Epoetin alfa accounted for $2 billion of this spending and was . . . [Full Text of this Article]


Source Information

Dr. Steinbrook (rsteinbrook@attglobal.net) is a national correspondent for the Journal.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.